UMB Bank n.a. Has $14.85 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• UMB Bank n.a. reduced its stake in Thermo Fisher Scientific by 6.2% during the second quarter, holding 36,615 shares worth approximately $14.8 million after selling 2,422 shares.
• Multiple hedge funds have significantly increased their investments, with GAMMA Investing LLC raising its position by over 60,000% and owning 2,419,331 shares valued at $1.2 billion.
• Analysts have a consensus rating of "Moderate Buy" for the stock, with an average price target of $588.35, reflecting positive expectations for future growth.

UMB Bank n.a. decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,615 shares of the medical research company's stock after selling 2,422 shares during the period. UMB Bank n.a.'s holdings in Thermo Fisher Scientific were worth $14,846,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of TMO. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth $25,000. CBIZ Investment Advisory Services LLC raised its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $30,000. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at $30,000. Finally, Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth $31,000. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last quarter. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 0.6%

Thermo Fisher Scientific stock traded down $3.07 during mid-day trading on Tuesday, reaching $471.92. 2,126,564 shares of the company's stock were exchanged, compared to its average volume of 2,392,631. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $178.20 billion, a P/E ratio of 27.33, a P/E/G ratio of 2.56 and a beta of 0.75. The company has a fifty day moving average of $472.99 and a 200-day moving average of $448.55. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. Raymond James Financial reiterated an "outperform" rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Finally, Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $490.00 to $550.00 in a report on Thursday, September 11th. Sixteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.